BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld
BioWorld
May 5, 2008
View Archived Issues
Discovery Labs Falls on Third Approvable Letter for Surfaxin
Discovery Laboratories Inc. received yet another approvable letter from the FDA for Surfaxin use in premature infants with respiratory distress syndrome, causing shares to fall more than 47 percent Friday. (BioWorld Today)
Read More
Critical Therapeutics Investors Balk Over Cornerstone Merger
Read More
Study Links Gene to High Blood Sugar, Not to Type II Diabetes
Read More
Panel Supports Approval of Cinryze in Preventing in HAE
Read More
Congress Debates User Fees for Foreign Drug Inspections
Read More
Earnings Roundup
Read More
Other News To Note
Read More
Clinic Roundup
Read More